Green Cross (006280) Stock Price, Fundamentals & Analysis

What 006280 does

Green Cross (006280) is a stock listed on the Korea Exchange in the Healthcare sector, specifically within the Drug Manufacturers – Specialty & Generic industry. The company, GC Biopharma Corp., develops and sells pharmaceutical drugs in South Korea, India, Taiwan, Japan, China, Malaysia, and internationally. Its portfolio includes over-the-counter products such as Acustop Cataplasma for analgesic and anti-inflammatory use, Kenhancer plaster, and Zenol Cool Type and Zenol Mild Hot Type for pain relief, as well as prescription injectables like Albumin-GCC for hypoalbuminemia, Antithrombin-III for hereditary deficiency, and products for hemophilia A and B. Green Cross is part of the broader Korean healthcare ecosystem alongside peers such as SD Biosensor (137310), Hanall Biopharma (009420), and Samsung Biologics (207940).

Key numbers explained

• 123,300 KRW is the current share price, the amount you would pay for one share right now.
• 1.41T KRW is the market capitalization, the total value of all outstanding shares; it places the company in the large-cap range.
• 29.4 is the forward P/E ratio, which divides the share price by expected future earnings per share; a higher number can reflect higher growth expectations.
• 1.22% is the dividend yield, the annual dividend payment expressed as a percentage of the share price.
• 0% is the share of earnings paid out as dividends, meaning the company currently retains all of its earnings rather than distributing them.
• 0.71 is beta, a measure of volatility relative to the market; a beta below 1 suggests the stock tends to move less than the overall market.
• 105,900 – 183,800 is the 52-week price range, showing the lowest and highest traded prices over the past year.
• -5.7% is the price change over the last 52 weeks, indicating the stock is down slightly compared to one year ago.

What to watch

Investors tracking Green Cross often watch its revenue growth, which has been negative at -15.8% year over year, and its profitability metrics, such as a profit margin of -2.5% and a return on equity of -4.5%. The debt-to-equity ratio of 70.8% is another common focus, as it shows how much of the company’s financing comes from debt relative to shareholder equity. Because the company operates in the healthcare sector, regulatory approvals, drug pipeline updates, and changes in healthcare policy in its key markets can be relevant factors. For those interested in the Korean market, Green Cross is part of the broader Korea Exchange stocks universe, which includes many healthcare peers.